Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss. This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.
Below you'll find the audio and video versions of the podcast, as well as the transcript and figures.
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript
Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs
The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly. He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC. Look for that here very soon.
Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…